Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.1
Power Rank trend -> Rising
Industry: Drug Manufacturers - Specialty & Generic
Follow @stockchartsai on TwitterIn the past 20 trading days, ELAN has been trading in a range between $14.30 and $12.62 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
ELAN is trading below resistance at $14.50, about 5% to the upside. There is support at $12.67 -8% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Elanco Animal Health $ELAN entered a Green zone 27 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $14.5455, a potential upside of 5.33% from the recent price of 13.81. The stock is trading 34.32% (potential upside) below its 52 week high of $18.55 and 72.19 % (potential downside) above its 52 week low of $8.02 - based on the recent price.
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry.
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP) Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind. , June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has been granted a positive opinion by the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP), paving the way for the product's marketing authorization in the European Union in the next 60 days. Source: PRNewsWire Thu, 12 Jun 2025 16:17:00 -0400 Sentiment: Neutral |
What Makes Elanco Animal Health (ELAN) a New Buy Stock Elanco Animal Health (ELAN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Source: Zacks Investment Research Tue, 10 Jun 2025 13:01:34 -0400 Sentiment: Positive |
ELAN vs. USPH: Which Stock Should Value Investors Buy Now? Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Elanco Animal Health Incorporated (ELAN) and U.S. Physical Therapy (USPH). But which of these two companies is the best option for those looking for undervalued stocks? Source: Zacks Investment Research Tue, 10 Jun 2025 12:46:17 -0400 Sentiment: Positive |
Is the Options Market Predicting a Spike in Elanco Animal Health Stock? Investors need to pay close attention to ELAN stock based on the movements in the options market lately. Source: Zacks Investment Research Mon, 09 Jun 2025 09:51:17 -0400 Sentiment: Neutral |
Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief. Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1 Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1 Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1 Leading veterinarians and canine dermatologists, including Drs. Source: PRNewsWire Thu, 05 Jun 2025 07:45:00 -0400 Sentiment: Neutral |
Stock Analyzed Each Night
Easily Upload Track Your Stocks
See Lists of Stocks Starting New Trends
The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.